Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

SSM Health Cancer Care, Madison, Wisconsin